← All trials
NCT00908752
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2009
- Primary completion
- Sep 28, 2012
- Completion date
- Jan 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 734
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.